Log in

OTCMKTS:ALPMY - ASTELLAS PHARMA/ADR Stock Price, Forecast & News

$17.18
+0.13 (+0.79 %)
(As of 02/20/2020 08:58 AM ET)
Today's Range
$17.05
Now: $17.18
$17.39
50-Day Range
$16.84
MA: $17.35
$18.36
52-Week Range
$12.77
Now: $17.18
$18.37
Volume49,187 shs
Average Volume41,006 shs
Market Capitalization$32.45 billion
P/E Ratio16.21
Dividend Yield1.84%
Beta0.84
Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceutical products worldwide. The company offers XTANDI and Eligard for the treatment of prostate cancer; Betanis/Myrbetriq/BETMIGA for overactive bladder (OAB) treatment; Vesicare forOAB treatment; Harnal/Omnic for functional symptoms associated with benign prostatic hyperplasia; VESOMNI for storage symptoms and voiding symptoms associated with benign prostatic hyperplasia; Prograf and Advagraf/Graceptor/ASTAGRAF XL/Prograf XL, animmunosuppressant; and Funguard/MYCAMINE, a candin-type antifungal agent. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ALPMY
CUSIPN/A
CIKN/A
Phone813-3244-3000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.83 billion
Cash Flow$1.32 per share
Book Value$5.72 per share

Profitability

Net Income$2.00 billion

Miscellaneous

Employees16,617
Outstanding Shares1,888,820,000
Market Cap$32.45 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive ALPMY News and Ratings via Email

Sign-up to receive the latest news and ratings for ALPMY and its competitors with MarketBeat's FREE daily newsletter.


ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) Frequently Asked Questions

What is ASTELLAS PHARMA/ADR's stock symbol?

ASTELLAS PHARMA/ADR trades on the OTCMKTS under the ticker symbol "ALPMY."

When did ASTELLAS PHARMA/ADR's stock split? How did ASTELLAS PHARMA/ADR's stock split work?

ASTELLAS PHARMA/ADR shares split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly created shares were distributed to shareholders after the market closes on Tuesday, April 1st 2014. An investor that had 100 shares of ASTELLAS PHARMA/ADR stock prior to the split would have 125 shares after the split.

How were ASTELLAS PHARMA/ADR's earnings last quarter?

ASTELLAS PHARMA/ADR (OTCMKTS:ALPMY) announced its quarterly earnings results on Wednesday, April, 25th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.15 by $0.05. The firm had revenue of $2.78 billion for the quarter. ASTELLAS PHARMA/ADR had a net margin of 17.25% and a return on equity of 17.71%. View ASTELLAS PHARMA/ADR's Earnings History.

What is the consensus analysts' recommendation for ASTELLAS PHARMA/ADR?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ASTELLAS PHARMA/ADR in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ASTELLAS PHARMA/ADR.

Has ASTELLAS PHARMA/ADR been receiving favorable news coverage?

News stories about ALPMY stock have trended negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. ASTELLAS PHARMA/ADR earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for ASTELLAS PHARMA/ADR.

Who are some of ASTELLAS PHARMA/ADR's key competitors?

What other stocks do shareholders of ASTELLAS PHARMA/ADR own?

Who are ASTELLAS PHARMA/ADR's key executives?

ASTELLAS PHARMA/ADR's management team includes the folowing people:
  • Mr. Kenji Yasukawa Ph.D., Pres, CEO & Director (Age 59)
  • Mr. Chikashi Takeda, CFO & Sr. Corp. Exec.
  • Mr. Fumiaki Sakurai, Chief Admin. Officer, Chief Ethics & Compliance Officer and Sr. Corp. Exec.
  • Ms. Linda Friedman, Gen. Counsel & VP
  • Dr. Sef P. Kurstjens, Chief Medical Officer and Pres of Global Devel. (Age 56)

How do I buy shares of ASTELLAS PHARMA/ADR?

Shares of ALPMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ASTELLAS PHARMA/ADR's stock price today?

One share of ALPMY stock can currently be purchased for approximately $17.18.

How big of a company is ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR has a market capitalization of $32.45 billion and generates $11.83 billion in revenue each year. The company earns $2.00 billion in net income (profit) each year or $1.04 on an earnings per share basis. ASTELLAS PHARMA/ADR employs 16,617 workers across the globe.View Additional Information About ASTELLAS PHARMA/ADR.

What is ASTELLAS PHARMA/ADR's official website?

The official website for ASTELLAS PHARMA/ADR is http://www.astellas.com/.

How can I contact ASTELLAS PHARMA/ADR?

ASTELLAS PHARMA/ADR's mailing address is 2-5-1 Nihonbashi-Honcho Chuo-Ku, Tokyo M0, 103-8411. The company can be reached via phone at 813-3244-3000.


MarketBeat Community Rating for ASTELLAS PHARMA/ADR (OTCMKTS ALPMY)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  205 (Vote Outperform)
Underperform Votes:  172 (Vote Underperform)
Total Votes:  377
MarketBeat's community ratings are surveys of what our community members think about ASTELLAS PHARMA/ADR and other stocks. Vote "Outperform" if you believe ALPMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALPMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/20/2020 by MarketBeat.com Staff

Featured Article: Inverted Yield Curve

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel